Table 2.
Surgical pathology and staging
| Total N = 20 |
M1a N = 5 |
M1b N = 15 |
|
|---|---|---|---|
| Time to surgery (mo) median (range) | 5 (3–11) | 5 (3–9) | 5 (3–11) |
| Procedure | |||
| RP + PLND | 14 (70%) | 1 (20%) | 13 (87%) |
| RP + PLND + RPLND | 6 (30%) | 4 (80%) | 2 (13%) |
| Primary tumor | |||
| ≤T2b | 3 (15%) | 2 (40%) | 1 (7%) |
| T3a | 5 (25%) | 0 (0%) | 5 (33%) |
| T3b | 9 (45%) | 1 (20%) | 8 (53%) |
| T4 | 3 (15%) | 2 (40%) | 1 (6%) |
| Vascular invasion | 14 (70%) | 5 (100%) | 9 (60%) |
| Positive surgical margin | 5 (25%) | 3 (60%) | 2 (13%) |
| Pathologic T stage* | |||
| Upstaged | 9 (45%) | 2 (40%) | 7 (46%) |
| Downstaged | 6 (30%) | 2 (40%) | 4 (27%) |
| No change | 5 (25%) | 1 (20%) | 4 (27%) |
| PLND | |||
| Pelvic LN removed, median (range) | 17 (9–25) | 17 (11–25) | 17 (9–25) |
| Number of positive LN, median (range) | 1 (0–13) | 3 (0–13) | 1 (0–9) |
| Number of patients with positive LN | 13 (65%) | 4 (80%) | 9 (60%) |
| Pathologic N stage* | |||
| Upstaged | 4 (20%) | 0 (0%) | 4 (27%) |
| Downstaged | 2 (10%) | 1 (20%) | 1 (7%) |
| No change | 14 (70%) | 4 (80%) | 10 (66%) |
| RPLND | N = 6 | N = 4 | N = 2 |
| Retroperitoneal LN removed, median (range) | 31 (22–48) | 40 (22–48) | 25 (23–27) |
| Number of positive LN, median (range) | 15 (0–30) | 21 (0–30) | 7 (0–14) |
| Number of patients with positive LN | 4 (67%) | 3 (75%) | 1 (50%) |
PLND, pelvic lymph node dissection; RPLND, retroperitoneal lymph node dissection.
*
Compared with initial clinical staging.